BTC$64,470.00+1.55%
ETH$1,682.40+1.24%
USDT$0.9996+0.01%
BNB$608.94+1.06%
USDC$0.9998+0.00%
XRP$1.15+1.82%
SOL$68.93+3.60%
TRX$0.3169+0.50%
FIGR_HELOC$1.02-1.53%
DOGE$0.0878+1.91%
HYPE$60.31-0.07%
USDS$0.9998+0.02%
LEO$9.73+0.30%
RAIN$0.013-0.19%
ZEC$422.21+3.66%
ADA$0.1719+1.57%
BTC$64,470.00+1.55%
ETH$1,682.40+1.24%
USDT$0.9996+0.01%
BNB$608.94+1.06%
USDC$0.9998+0.00%
XRP$1.15+1.82%
SOL$68.93+3.60%
TRX$0.3169+0.50%
FIGR_HELOC$1.02-1.53%
DOGE$0.0878+1.91%
HYPE$60.31-0.07%
USDS$0.9998+0.02%
LEO$9.73+0.30%
RAIN$0.013-0.19%
ZEC$422.21+3.66%
ADA$0.1719+1.57%
Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.